Penumbra posts Q3 2026 revenue growth as Boston Scientific acquisition remains pending

Penumbra reported third‑quarter 2026 revenue of $410.15 million, up 15.6% year‑over‑year, and net income of $42.28 million, yielding GAAP EPS of $1.07. Gross profit margin improved to 68.3%. The company will not give full‑year guidance because its acquisition by Boston Scientific is still pending, with the deal expected to close in early 2027.

The lack of full‑year guidance leaves investors without a near‑term earnings outlook (the company says it will not provide guidance due to the pending acquisition)【1】. The pending Boston Scientific deal could affect Penumbra’s valuation and future cash‑flow expectations.

Sources